IMPROVE-IT study shows cardiovascular benefit

The IMPROVE-IT study, the large cardiovascular-outcomes trial that showed a clinical benefit to adding ezetimibe to statin therapy in post–acute coronary syndrome patients, is now published. The trial included more than 18,000 patients showing that the combination of ezetimibe/simvastatin leads to fewer cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction,